Medpace (Cincinnati, Ohio) is a contract research organization (CRO) with a wholly owned and integrated imaging core lab that offers a suite of global imaging services for medical device and biopharmaceutical development. According to New York City-based Medidata, by using its Rave imaging, Medpace’s imaging core lab will:
- Provide Medpace customers with a single, familiar location for site data entry and image uploads.
- Optimize resources and workflow, reduce manual reconciliation steps, increase data visibility and create a single data repository on a unified trial platform.
- Compute quantitative imaging biomarkers for clinical trials in oncology, metabolic disease and neuroscience.
- Create an integrated workflow to determine patient eligibility, monitor disease progression or response, and make clinical decisions that provide customers with a more streamlined and effective approach for managing vital imaging components of their study.
“Medidata is transforming the way the healthcare industry incorporates and leverages imaging in clinical trials,” said Medidata co-CEO Glen de Vries in a news release. “As drug and medical device development depend more on medical imaging, it’s more important than ever to simplify and unify image and data collection. This helps to minimize risk and complexity, and ensures accurate, rapid completion of clinical studies so patients can more quickly benefit from new therapeutics.”
More than 50% of all studies use medical imaging to help determine the efficacy of new drugs and devices and 95% when it is an oncology study, according to Medidata, which is part of Dassault Systèmes. Its Rave imaging is an end-to-end, cloud-based platform for image management in clinical trials. This includes image capture, advanced edit checks, workflow, form design, electronic data capture (EDC) connection and intelligent archiving. Medidata said it processes more than 500 million images annually from nearly 800 studies.
“Through our partnership with Medidata, Medpace is now able to provide seamless integration of our quantitative image analysis pipelines with Medidata’s Rave Imaging system and database,” said Dr. Daniel O’Leary, chief medical officer for Medpace’s imaging core lab. “The combination of these tools produces the most powerful imaging trial management environment currently available to the clinical trial market.”